CyT49

General

Cell Line

hPSCreg name VCYTe001-A
Cite as:
VCYTe001-A (RRID:CVCL_B850)
Alternative name(s)
CyT49
Cell line type Human embryonic stem cell (hESC)
Similar lines No similar lines found.
Last update 22nd May 2019
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator ViaCyte, Inc. (VCYT)
Owner Stem Cell Derivation
Distributors
Derivation country United States

External Databases

BioSamples SAMEA17469418
Cellosaurus CVCL_B850
NIHhESC NIHhESC-10-0041
Wikidata Q54817112

General Information

Publications
* Is the cell line readily obtainable for third parties?
No

Donor Information

General Donor Information

Sex male

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.
Disease associated phenotypes no phenotypes
Family history No
Is the medical history available upon request? No
Is clinical information available? No

Karyotyping (Donor)

Has the donor karyotype been analysed?
Yes
46, XY

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA17470168

Ethics

Was the embryo established purely for research purposes? No
Have both parents consented to the use of the embryo for ESC derivation? Yes
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Alternatives to consent are available? Yes
Alternatives to consent
Alternative consent approval number NIHhESC-10-0041
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent expressly prevent the derivation of pluripotent stem cells? No
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? Ethical & Independent Review Services
Approval number 04078-01D

hESC Derivation

Date of derivation 2005-11-02
Embryo stage Blastula with ICM and Trophoblast
Supernumerary embryos from IVF treatment?
Yes
Separation of research and IVF treatment?
Yes
PGD Embryo?
No
Expansion status 2
Stephenson 2007
ICM morphology C
Stephenson 2007
Trophectoderm morphology b
Stephenson 2007
ZP removal technique Chemical
Cell isolation None
Cell seeding Embryo
Derived under xeno-free conditions?
No
Derivation under GMP?
Yes
Available as clinical grade?
No

Culture Conditions

Surface coating Non coated
Feeder cells Human Dermal Fibroblasts
Passage method Mechanically
O2 Concentration 20 %
CO2 Concentration 8 %
Medium Other medium:
Base medium: DMEM/F12
Main protein source: Knock-out serum replacement
Serum concentration: 20 %
Supplements
L-Alanyl-L-Glutamine 1 %
Non-Essential Amino Acids 1 %
Penicillin/Streptomycin 1 %
2-Mercaptoethanol 0.1 mM
Activin A 25 ng/ml
FGF2 10 ng/ml

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
NANOG
Yes
SSEA-4
Yes
TRA 1-60
Yes
TRA 1-81
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vivo teratoma
In vitro directed differentiation
Mesoderm
Ont Id: UBERON_0000926
In vivo teratoma
Ectoderm
Ont Id: UBERON_0000924
In vivo teratoma

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46, XY
Passage number: 12
Karyotyping method: G-Banding

Other Genotyping (Cell Line)